Search results for "Bronchodilators"

showing 2 items of 2 documents

The use of bronchodilators in the treatment of airway obstruction in elderly patients

2006

Abstract Ageing is associated with important anatomical, physiological and psychosocial changes that may have an impact on the management of obstructive airway diseases (asthma and chronic obstructive pulmonary disease (COPD)) and on their optimal therapy. Ageing-related modifications might be responsible for a different effectiveness of bronchodilators in the elderly patients as compared to younger subjects. Furthermore, the physiological involution of organs and the frequent comorbidity, often interfere with pharmacokinetics of bronchodilator drugs used in asthma and COPD. This review will focus on the use of bronchodilators in the elderly, with particular attention to the achievable goal…

Pulmonary and Respiratory Medicinemedicine.medical_specialtymedicine.drug_classSettore MED/10 - Malattie Dell'Apparato RespiratorioCholinergic AntagonistsPulmonary Disease Chronic ObstructiveElderlyBronchodilatorasthma COPDmedicineHumansPharmacology (medical)Intensive care medicineAdverse effectAsthmaAgedCOPDbusiness.industryBiochemistry (medical)Airway obstructionAdrenergic beta-Agonistsmedicine.diseaseComorbidityrespiratory tract diseasesBronchodilator AgentsbronchodilatorsAirway ObstructionBronchodilator AgentsXanthinesAirwaybusiness
researchProduct

The Effect of Tiotropium in Symptomatic Asthma Despite Low- to Medium-Dose Inhaled Corticosteroids: A Randomized Controlled Trial.

2014

BackgroundTiotropium, a once-daily long-acting anticholinergic bronchodilator, has demonstrated efficacy in patients with asthma who were symptomatic despite treatment with medium- to high-dose inhaled corticosteroids (ICS).ObjectiveThe objective of this study was to evaluate the efficacy and safety of once-daily tiotropium Respimat (5 μg or 2.5 μg), compared with placebo Respimat, as add-on therapy to low- to medium-dose ICS for adults with symptomatic asthma.MethodsA phase III, double-blind, placebo-controlled trial was conducted (NCT01316380). Adults with symptomatic asthma receiving low- to medium-dose ICS (200-400 μg budesonide or equivalent dose) and a pre-bronchodilator forced expira…

SpirometryBudesonideAdultMaleRespimatmedicine.drug_classSymptomaticAnticholinergicMildPlacebo03 medical and health sciences0302 clinical medicineBronchodilatorsAdrenal Cortex HormonesBronchodilatorControlAdministration InhalationImmunology and AllergyMedicineHumans030212 general & internal medicineTiotropium BromideBudesonideAnticholinergic; Asthma; Bronchodilators; Control; GINA; ICS; Mild; Respimat; Symptomatic; Tiotropium; Administration Inhalation; Adrenal Cortex Hormones; Adult; Asthma; Bronchodilator Agents; Budesonide; Disease Progression; Drug Combinations; Female; Humans; Male; Placebo Effect; Spirometry; Tiotropium Bromide; Treatment Outcome; Immunology and AllergyAsthmamedicine.diagnostic_testbusiness.industryTiotropiumTiotropium bromidemedicine.diseasePlacebo EffectGINAAsthmarespiratory tract diseasesRespimatBronchodilator AgentsDrug CombinationsTreatment OutcomeInhalation030228 respiratory systemTolerabilityICSSpirometryAnesthesiaAdministrationDisease ProgressionFemalebusinessmedicine.drugThe journal of allergy and clinical immunology. In practice
researchProduct